Search for a trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of ALKS 7119 in Healthy Adults

Primary:* Evaluate the safety and tolerability of ALKS 7119 following oral administration of multiple ascending doses of ALKS 7119 in healthy male and female adultsSecondary:* Evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7119…

A Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ALKS 7119 in Healthy Male Adults

To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ALKS 7119 following oral administration of single ascending doses of ALKS 7119 in healthy male adults

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter
Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are
Asymptomatic At Risk for Developing Alzheimer*s Dementia

Primary Objective:The primary objective of this study is to determine whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive…

A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer*s Disease (Prodromal AD).

To assess the efficacy of two doses of MK-8931 based on overall clinical progression in subjects with prodromal Alzheimer's Disease (AD).To assess the efficacy of two doses of MK-8931 in slowing clinical decline and disease progression in…

Medical Nutrition in prodromal Alzheimer's Disease, a double-blind controlled 24-month study, with four times a 12 month extension study.

To evaluate the effect of Souvenaid® on cognition in patïents with mild cognitive impairment after 24 months.

A randomized, double-blind, placebo and reference controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of Memogain administered by intranasal application to healthy elderly subjects.

Objective(s)• To evaluate the safety and tolerability after intranasal administration of ascending multiple doses of Memogain in healthy elderly subjects.• To evaluate the PK after intranasal administration of ascending multiple doses of Memogain in…

Evaluation of 18F-AV-1451 kinetic modeling in patients in Alzheimer's disease and healthy controls

The primary objectives of this study are:* To evaluate tracer kinetic models for the purpose of quantifying specific binding of 18F-AV-1451 in cross sectional and longitudinal applications; and* To evaluate simplified methods for quantification of…

A Phase I Partially Blinded Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivastigmine with Glycopyrrolate or Trospium in Healthy Elderly Volunteers

Primary:To establish the safety and tolerability of rivastigmine when given with concomitant glycopyrrolate at an accelerated dose escalation schedule up to 12 mg BID.To establish the safety and tolerability of rivastigmine when given with…

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer*s Disease

1. To demonstrate the clinical efficacy of leuco-methylthioninium bis(hydromethanesulfonate) (also known as LMTM,TRx0237) in mild Alzheimer*s disease as assessed by change from baseline on:• Alzheimer*s Disease Assessment Scale - Cognitive Subscale…

Efficacy and safety of delta-9-tetrahydrocannabinol (delta-THC) in behavioural disturbances in dementia

The primary objective is to evaluate the efficacy of Namisol® in the management of behavioural disturbances in patients with dementia. Secondary objectives are:- To evaluate the efficacy of Namisol® on secondary outcome measures, such as quality of…

Practical biomarkers for the early detection of dementia

Our projects aim to identify (a combination of) putative diagnostics markers for Alzheimer's disease that allow for accurate discrimination and at the same time can be more readily implemented than the currently available markers, i.e. cheaper…

Brain Network analysis in early onset dementias: Magnetoencephalographic measurements.

With this research we intend to fill the gap described in the previous chapter by:1) Detecting functional network changes in several causes of early-onset dementia and to characterize the specific changes for each dementia cause.2) Relating specific…

Neural Correlates of Apathy In Mild Cognitive Impairment (MCI)

The main objective of this study is to determine the neural correlates of apathy. These neural correlates will be compared with the neuropsychological tests At a later stage, the predictive value of the neural correlates will also be assessed.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

2.1 Primary Objectives• Evaluate the safety and tolerability of 2 fixed doses of FRM-0334 (300 and 500 mg daily in 2 sequential periods) over 28 days in subjects with prodromal to moderate FTD-GRN• Assess the PD effects of FRM-0334 on the change…

A single-center, open-label, randomized, 3-way crossover study to compare the rate and extent of Rivastigmine absorption from two different formulations of 7 day Rivastigmine transdermal systems (7-day RTS) with 24-hour Exelon® patches applied daily for 7 days in healthy male and female subjects.

To compare the rate and extent of rivastigmine absorption from two different formulations of 7-day rivastigmine transdermal systems (7-day RTS) with 24-hour Exelon® patch applied daily for 7 days in healthy adult male and female subjects.To assess…

Subjective cognitive impairment and mild cognitive impairment: a sign of incipient Alzheimer*s disease?
* A longitudinal study of functional and structural brain changes in healthy older adults with and without cognitive complaints.

1. To investigate the differences between healthy older adults with and without cognitive complaints (SCI) and MCI patients in: a) resting state functional connectivity; b) brain structure; and c) cognitive function. 2. To investigate longitudinal…

Effects of a Neurofeedback Treatment on Psychological, Cognitive and Physiological (EEG) outcomes in patients suffering from cognitive decline

So far, only a few case-studies have been tried using neurofeedback in the treatment of dementia / cognitive decline. These indicate that there are behavioural changes and emotional changes next to cognitive changes. This will be the focus of this…

Healthy Aging: aerobic exercise, strength training and dementia.

The objective is to investigate the effects of a combined strength and aerobic exercise program on cognition, physical functioning, social functioning and ADL.

Long-term effects of Advanced Driver Assistence Systems (ADAS) on driving performance of older drivers with and without mild cognitive or physical impairments: A driving simulator study

The present PhD thesis focuses on the investigation of ADAS and the older driver. Even though, recent research investigated the effects of ADAS on driving performance, little is known about the long-term effects of the systems on performance.…

Elderly patients suspected of cognitive decline by family physicians; a cluster randomized controlled trial to improve the diagnostic and care process

To evaluate the feasibility and (cost) effectiveness of an intervention to improve the quality of dementia care and the wellbeing of home dwelling persons with dementia and their main informal caregiver.